13MAY

CellCentric raises Europe's largest 2026 biotech round

4 min read

20:05UTC

CellCentric closed a $220m Series D on 5 May led by Venrock Healthcare Capital Partners, with Pfizer and Fidelity co-investing: Europe's largest private biotech financing of 2026, drawn entirely from private capital.

← Back to State capital lands on UK tech in nine days Jump to analysis ↓

TechnologyDeveloping

Key takeaway

CellCentric's $220m Series D with Pfizer proves UK oncology commands US-sized rounds without public subsidy.

CellCentric closed a $220m Series D on 5 May 2026, which BioSpace and BioPharma Dive reported as the largest private biotech financing in Europe in 2026. ¹ Venrock Healthcare Capital Partners led; Fidelity Management and Research, Sofinnova Partners, HBM Healthcare, RA Capital Management, Forbion, Pfizer, Avego BioScience Capital, and the American Cancer Society BrightEdge initiative co-invested.

The capital funds Phase 2 DOMMINO-1 trials, running in both the UK and the United States, for inobrodib, an oral p300/CBP (a histone acetyltransferase target) inhibitor for relapsed and refractory multiple myeloma. Phase 3 (DOMMINO-2) is planned for H2 2026. inobrodib's oral formulation is clinically significant: multiple myeloma treatment is predominantly infusion-based today, and an oral option changes the outpatient economics of treatment substantially for a patient population that requires long-term maintenance therapy.

Pfizer's entry at Phase 2 stage is the signal that compresses the typical trade-sale timeline. When a major pharmaceutical company enters a Series D alongside a Phase 2 readout, it is typically conducting buy-versus-build analysis in parallel: the equity position gives Pfizer visibility into the DOMMINO-1 data before it is public. For CellCentric, that creates a dual path to liquidity: a Phase 3 success that supports an independent listing, or an acquisition by a strategic already inside the syndicate.

No UK public investor participated in the round. CellCentric kept its Phase 2 and capital fully in the UK without any state anchor. At $220m with Pfizer in, public capital was neither needed nor sought. The FCA and PRA had cut SM&CR (Senior Managers and Certification Regime) certification roles by 15% on 22 April , reducing regulatory overhead for authorised financial participants in biotech rounds, a signal that the UK regulatory environment is loosening at both the investment and company level simultaneously. UK oncology founders with credible Phase 2 data can now argue for a US-sized Series D from London; the Boston relocation pressure has dropped a notch.

Deep Analysis

In plain English

CellCentric is developing a cancer drug called inobrodib for multiple myeloma, a blood cancer that affects the bone marrow. Inobrodib is taken as a tablet rather than an infusion, which matters enormously for patients who need long-term treatment: monthly infusion clinic visits over years are exhausting and disruptive to daily life. The company raised $220m in May 2026, described as the largest private funding round for a European biotech company in 2026. Pfizer, one of the world's largest pharmaceutical companies, invested alongside US and European specialist healthcare funds. The money funds Phase 2 clinical trials in the UK and US, with a larger Phase 3 global trial planned for the second half of 2026. No UK government money joined the round; the BBB's £40m-per-company cap would have covered less than 20% of the $220m raise, and Venrock, Pfizer, and Fidelity filled the syndicate without it.

Deep Analysis

Root Causes

Multiple myeloma's relapsed/refractory segment represents a structural market failure in oncology: patients exhaust approved therapies faster than new approvals arrive, creating a persistent unmet need that Pfizer, J&J, and BMS have all tried to address through acquisitions and licensing.

CellCentric's oral formulation addresses a specific constraint in the relapsed segment: patients receiving maintenance therapy over years find infusion-based treatments logistically unsustainable, and an oral agent that maintains efficacy while eliminating infusion clinic visits has health-economics advantages independent of clinical differentiation.

The DOMMINO-1 Phase 2 running simultaneously in the UK and US is a regulatory strategy as much as a clinical one: dual-jurisdiction Phase 2 data compresses the time to Biologics License Application in the US while supporting a UK Medicines and Healthcare products Regulatory Agency (MHRA) submission from the same dataset.

What could happen next?

Opportunity
Pfizer's Series D equity position creates a structured acquisition option that CellCentric can exercise via a Phase 3 success: a bilateral deal with Pfizer already inside the syndicate avoids a competitive auction process and provides balance-sheet certainty for the development programme.
Consequence
CellCentric's $220m with no BBB participation, on the same day as Cytospire's oversubscribed BBB-backed round, establishes that UK oncology companies with credible Phase 2 assets do not require public co-investment to close US-scale rounds; the BBB's additionality case is stronger in early-stage rounds where private lead investors are absent.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: Adaptimmune's 2020 $200m Series D, led by Syncona and BlackRock with no UK public investor, followed by a Nasdaq listing in 2020, established that UK oncology companies with Phase 2 assets can raise US-sized private rounds from London without relocating. CellCentric's $220m with Pfizer in, also without public capital, follows the same structural pattern: international institutional lead, strategic pharma co-investor, UK clinical infrastructure.

Counter-parallel: Autolus Therapeutics listed on Nasdaq in 2018 on strong preclinical data for CAR-T, raised further capital at IPO, but then encountered clinical holds in 2021 and 2022 that compressed the share price by over 80% from its 2018 high.

CellCentric's Phase 2 stage is further along than Autolus at listing, but relapsed/refractory multiple myeloma is a patient population that has typically received three or more prior lines of therapy, making response durability the critical gate that Phase 3 must clear.

At $220m Series D, CellCentric's pre-money valuation implies a substantial premium to the typical Phase 2-entry multiple myeloma asset. Pfizer's participation changes the acquisition economics: a strategic investor in the syndicate typically marks a lower acquisition premium at Phase 3 success, because the deal is already partially priced in through the equity position.

For independent shareholders, Pfizer's presence compresses the upside of a competitive acquisition process while reducing the downside of a failed Phase 3 by providing a buyer-of-last-resort if data are ambiguous.

No UK public investor participated. At $220m with Pfizer in, the BBB's £40m per-company cap would have represented a sub-20% contribution to a round where private institutional appetite was already sufficient. This is the structural complement to the Cytospire additionality question: in the largest UK biotech round of 2026, public capital was neither needed nor sought.

Consensus view: BioPharma Dive and Evaluate Vantage assess Pfizer's Series D participation as a structured buy-versus-build option: the equity stake gives Pfizer access to DOMMINO-1 readout data before it is public, at a fraction of the cost of a pre-Phase-3 acquisition. Sofinnova Partners' analyst team in Paris views the oral p300/CBP mechanism as clinically differentiated from HDAC (histone deacetylase) inhibitors, which have struggled with tolerability in haematology.

Counter-view: RA Capital Management's life sciences team argues the p300/CBP target has failed in multiple prior oncology programmes, including the GSK2801 programme that was discontinued in 2019 due to insufficient efficacy in solid tumours. inobrodib's multiple myeloma indication avoids the solid tumour failure mode, but the mechanism's track record means a higher-than-typical Phase 2 hurdle applies.

Key tension: Whether p300/CBP inhibition in multiple myeloma can produce durable responses in relapsed/refractory patients, or whether the mechanism will reproduce the tolerability-versus-efficacy tradeoff that ended earlier p300/CBP programmes in adjacent cancers.

First Reported In

Update #4 · State capital lands on UK tech in nine days

BioSpace· 13 May 2026

Read original →

Different Perspectives

Australian Department of Defence (AUKUS AI for Acoustics partner)

Rowden Technologies holds active AUKUS AI for Acoustics contracts with the UK, US, and Australian defence establishments. The NWF's £25m investment in Rowden on 13 May brings UK sovereign capital directly into a trilateral programme, which from Canberra's perspective places additional UK government skin-in-the-game on a programme Australia co-funds and co-develops.

Sofinnova Partners (European VC co-investor in Cytospire Series A)

Sofinnova participated alongside the BBB in Cytospire's oversubscribed £61m Series A on 5 May, demonstrating that the BBB's expanded direct mandate is attracting established European specialist biotech funds rather than replacing them. European VCs see the BBB's cornerstone position as a signal reducing UK biotech execution risk rather than crowding out private capital.

Temasek (Singapore sovereign co-investor in Isomorphic Series B)

Singapore's Temasek co-invested alongside the UK's SAIU in Isomorphic's $2.1bn round, treating the same Alphabet-majority company as an acceptable sovereign co-investment target. Temasek's participation normalises the structure: multiple sovereign wealth funds backed the same round, strengthening the precedent that UK-headquartered Alphabet subsidiaries qualify for state investment.

Alphabet / Google (majority Isomorphic shareholder, Mountain View)

Alphabet co-invested via GV and CapitalG in the same Isomorphic Series B round that received UK sovereign backing, placing US corporate capital and UK public capital in the same syndicate without any governance asymmetry. SAIU's minority stake validates Isomorphic's strategic value without constraining Alphabet's control over IP, geography, or exit decisions.

DSIT / Liz Kendall, Secretary of State for Science

DSIT framed the Isomorphic investment as backing a British-founded and headquartered company advancing UK AI capability, and described the nine-day sovereign deployment sprint as evidence the government's industrial strategy is operational. The department has not addressed the ownership question, the absence of eligibility criteria, or the pace-versus-doctrine tension in the BBB mandate.

Beauhurst / UK startup data analysts

Five sub-£50m rounds closed in nine days with zero VCT-backed angel networks on any cap table, confirming the post-cut investor map is forming fast in the £4m–£40m band. The gap is structural: 36.7% of university spinouts raised below £500,000 in 2025, a tier neither the SAIU nor the BBB direct mandate touches.